References
- Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003). Coronavirus Main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science (New York, N.Y.), 300(5626), 1763–1767. https://doi.org/https://doi.org/10.1126/science.1085658
- Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020). The proximal origin of SARS-CoV-2. Nature Medicine, 26(4), 450–452. https://doi.org/https://doi.org/10.1038/s41591-020-0820-9
- Arun, K. G., Sharanya, C. S., Abhithaj, J., Francis, D., & Sadasivan, C. (2020). Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target. Journal of Biomolecular Structure and Dynamics. https://doi.org/https://doi.org/10.1080/07391102.2020.1779819
- Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews. Drug Discovery, 3(8), 673–683. https://doi.org/https://doi.org/10.1038/nrd1468
- Baden, L. R., & Rubin, E. J. (2020). Covid-19—The search for effective therapy. The New England Journal of Medicine, 382(19), 1851–1852. https://doi.org/https://doi.org/10.1056/NEJMe2005477
- Bhardwaj, V. K., Singh, R., Sharma, J., Rajendran, V., Purohit, R., & Kumar, S. (2020). Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. Journal of Biomolecular Structure and Dynamics.https://doi.org/https://doi.org/10.1080/07391102.2020.1766572
- Bowers, K. J., Chow, D. E., Xu, H., Dror, R. O., Eastwood, M. P., Gregersen, B. A., Klepeis, J. L., Kolossvary, I., Moraes, M. A., Sacerdoti, F. D., Salmon, J. K., Shan, Y., & Shaw, D. E. (2006). Scalable algorithms for molecular dynamics simulations on commodity clusters [Paper presentation]. SC ’06: Proceedings of the 2006 ACM/IEEE Conference on Supercomputing (pp. 43–43). https://doi.org/https://doi.org/10.1109/SC.2006.54
- Carragher, N. (2006). Calpain inhibition: A therapeutic strategy targeting multiple disease states. Current Pharmaceutical Design, 12(5), 615–638. https://doi.org/https://doi.org/10.2174/138161206775474314
- Chatel-Chaix, L., Baril, M., & Lamarre, D. (2010). Hepatitis C virus NS3/4A protease inhibitors: A light at the end of the tunnel. Viruses, 2(8), 1752–1765. https://doi.org/https://doi.org/10.3390/v2081752
- Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007). Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clinical Microbiology Reviews, 20(4), 660–694. https://doi.org/https://doi.org/10.1128/CMR.00023-07
- Deeks, E. D. (2014). Cobicistat: A review of its use as a pharmacokinetic enhancer of Atazanavir and Darunavir in patients with HIV-1 infection. Drugs, 74(2), 195–206. https://doi.org/https://doi.org/10.1007/s40265-013-0160-x
- Dixon, S. L., Smondyrev, A. M., Knoll, E. H., Rao, S. N., Shaw, D. E., & Friesner, R. A. (2006). PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. Journal of Computer-Aided Molecular Design, 20(10–11), 647–671. https://doi.org/https://doi.org/10.1007/s10822-006-9087-6
- Fakhar, Z., Faramarzi, B., Pacifico, S., & Faramarzi, S. (2020). Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic. Journal of Biomolecular Structure and Dynamics.https://doi.org/https://doi.org/10.1080/07391102.2020.1801510
- Flanagan, S., Crawford-Jones, A., & Orkin, C. (2014). Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection. Expert Review of Clinical Pharmacology, 7(6), 691–704. https://doi.org/https://doi.org/10.1586/17512433.2014.956091
- Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49(21), 6177–6196. https://doi.org/https://doi.org/10.1021/jm051256o
- Ghosh, R., Chakraborty, A., Biswas, A., & Chowdhuri, S. (2020). Identification of polyphenols from Broussonetia papyrifera as SARS CoV-2 main protease inhibitors using in silico docking and molecular dynamics simulation approaches. Journal of Biomolecular Structure and Dynamics.https://doi.org/https://doi.org/10.1080/07391102.2020.1802347
- Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 47(7), 1750–1759. https://doi.org/https://doi.org/10.1021/jm030644s
- Hilgenfeld, R. (2014). From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design. The FEBS Journal, 281(18), 4085–4096. https://doi.org/https://doi.org/10.1111/febs.12936
- Hosseini, F. S., & Amanlou, M. (2020). Simeprevir, Potential candidate to repurpose for coronavirus infection: Virtual screening and molecular docking study. https://doi.org/https://doi.org/10.20944/preprints202002.0438.v1
- Ibrahim, M. A. A., Abdeljawaad, K. A. A., Abdelrahman, A. H. M., & Hegazy, M.-E F. (2020). Natural-like products as potential SARS-CoV-2 Mpro inhibitors: In-silico drug discovery. Journal of Biomolecular Structure and Dynamics.https://doi.org/https://doi.org/10.1080/07391102.2020.1790037
- Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., Duan, Y., Yu, J., Wang, L., Yang, K., Liu, F., Jiang, R., Yang, X., You, T., Liu, X., … Yang, H. (2020). Structure of M pro from COVID-19 virus and discovery of its inhibitors. Nature, 582(7811), 289–289. https://doi.org/https://doi.org/10.1038/s41586-020-2223-y
- Kaminski, G. A., Friesner, R. A., Tirado-Rives, J., & Jorgensen, W. L. (2001). Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. The Journal of Physical Chemistry B, 105(28), 6474–6487. https://doi.org/https://doi.org/10.1021/jp003919d
- Kapusta, K., Kar, S., Collins, J. T., Franklin, L. M., Kolodziejczyk, W., Leszczynski, J., & Hill, G. A. (2020). Protein reliability analysis and virtual screening of natural inhibitors for SARS-CoV-2 main protease (Mpro) through docking, molecular mechanic & dynamic, and ADMET profiling. Journal of Biomolecular Structure and Dynamics.https://doi.org/https://doi.org/10.1080/07391102.2020.1806930
- Li, Z., Yao, F., Xue, G., Xu, Y., Niu, J., Cui, M., Wang, H., Wu, S., Lu, A., Zhong, J., & Meng, G. (2019). Antiviral effects of simeprevir on multiple viruses. Antiviral Research, 172, 104607. https://doi.org/https://doi.org/10.1016/j.antiviral.2019.104607
- Lyne, P. D., Lamb, M. L., & Saeh, J. C. (2006). Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. Journal of Medicinal Chemistry, 49(16), 4805–4808. https://doi.org/https://doi.org/10.1021/jm060522a
- Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27(3), 221–234. https://doi.org/https://doi.org/10.1007/s10822-013-9644-8
- Majumdar, A., Kitson, M. T., & Roberts, S. K. (2016). Systematic review: Current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Alimentary Pharmacology & Therapeutics, 43(12), 1276–1292. https://doi.org/https://doi.org/10.1111/apt.13633
- Mitjà, O., & Clotet, B. (2020). Use of antiviral drugs to reduce COVID-19 transmission. The Lancet. Global Health, 8(5), e639–e640. https://doi.org/https://doi.org/10.1016/S2214-109X(20)30114-5
- Prajapat, M., Sarma, P., Shekhar, N., Avti, P., Sinha, S., Kaur, H., Kumar, S., Bhattacharyya, A., Kumar, H., Bansal, S., & Medhi, B. (2020). Drug targets for corona virus: A systematic review. Indian Journal of Pharmacology, 52(1), 56–65. https://doi.org/https://doi.org/10.4103/ijp.IJP_115_20
- Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews. Drug Discovery, 18(1), 41–58. https://doi.org/https://doi.org/10.1038/nrd.2018.168
- Scott, L. J. (2019). Larotrectinib: First global approval. Drugs, 79(2), 201–206. https://doi.org/https://doi.org/10.1007/s40265-018-1044-x
- Sharma, P., Vijayan, V., Pant, P., Sharma, M., Vikram, N., Kaur, P., Singh, T. P., & Sharma, S. (2020). Identification of potential drug candidates to combat COVID-19: A structural study using the main protease (mpro) of SARS-CoV-2. Journal of Biomolecular Structure and Dynamics.https://doi.org/https://doi.org/10.1080/07391102.2020.1798286
- Sun, H. (2008). Pharmacophore-based virtual screening. Current Medicinal Chemistry, 15(10), 1018–1024. https://doi.org/https://doi.org/10.2174/092986708784049630
- Tawari, N. R., & Degani, M. S. (2010). Pharmacophore mapping and electronic feature analysis for a series of nitroaromatic compounds with antitubercular activity. Journal of Computational Chemistry, 31(4), 739–751. https://doi.org/https://doi.org/10.1002/jcc.21371
- Wang, C., Liu, Z., Chen, Z., Huang, X., Xu, M., He, T., & Zhang, Z. (2020). The establishment of reference sequence for SARS-CoV-2 and variation analysis. Journal of Medical Virology, 92(6), 667–674. https://doi.org/https://doi.org/10.1002/jmv.25762
- Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., … Wilson, M. (2018). DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46(D1), D1074–D1082. https://doi.org/https://doi.org/10.1093/nar/gkx1037
- Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., Yuan, M.-L., Zhang, Y.-L., Dai, F.-H., Liu, Y., Wang, Q.-M., Zheng, J.-J., Xu, L., Holmes, E. C., & Zhang, Y.-Z. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265–269. https://doi.org/https://doi.org/10.1038/s41586-020-2008-3
- Xie, M., & Chen, Q. (2020). Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 94, 119–124. https://doi.org/https://doi.org/10.1016/j.ijid.2020.03.071
- Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science (New York, N.Y.), 368(6489), 409–412. https://doi.org/https://doi.org/10.1126/science.abb3405
- Zhang, X. (2016). Direct anti-HCV agents. Acta Pharmaceutica Sinica. B, 6(1), 26–31. https://doi.org/https://doi.org/10.1016/j.apsb.2015.09.008
- Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., Chen, H.-D., Chen, J., Luo, Y., Guo, H., Jiang, R.-D., Liu, M.-Q., Chen, Y., Shen, X.-R., Wang, X., … Shi, Z.-L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/https://doi.org/10.1038/s41586-020-2012-7